Michael Dragunow

Title: Michael Dragunow: Innovator in Neuroprotection

Introduction

Michael Dragunow is a prominent inventor based in Auckland, New Zealand. He has made significant contributions to the field of neuroprotection through his innovative research and inventions. His work focuses on developing therapeutic agents that can combat neurodegeneration and related disorders.

Latest Patents

Michael Dragunow holds a patent titled "Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration." This invention provides analogs and peptidomimetics of glycyl-L-prolyl-L-glutamic acid (GPE). In particular, this invention relates to GPE analogs and peptidomimetics that are anti-apoptotic, anti-necrotic, and have neuroprotective effects. These agents are useful in treating neurodegeneration and behavioral disorders caused by toxins, traumatic brain injury, and autoimmune disorders of the brain, such as multiple sclerosis, and in reducing seizures. He has 1 patent to his name.

Career Highlights

Michael Dragunow has had a distinguished career in the field of neuroscience. He is currently associated with Neuren Pharmaceuticals Limited, where he continues to work on innovative solutions for neurodegenerative diseases. His research has garnered attention for its potential impact on treatment options for various neurological conditions.

Collaborations

Michael has collaborated with notable professionals in his field, including Peter David Gluckman and Gregory Brian Thomas. These collaborations have further enhanced the scope and impact of his research.

Conclusion

Michael Dragunow is a key figure in the development of neuroprotective therapies, with a focus on innovative solutions for neurodegeneration. His contributions to the field are paving the way for advancements in treatment options for neurological disorders.